tradingkey.logo

Sutro Biopharma Announces Strategic Portfolio Review Resulting In The Prioritization Of Its Next-Generation Adc Pipeline

ReutersMar 13, 2025 9:34 PM

- Sutro Biopharma Inc STRO.O:

  • SUTRO BIOPHARMA ANNOUNCES STRATEGIC PORTFOLIO REVIEW RESULTING IN THE PRIORITIZATION OF ITS NEXT-GENERATION ADC PIPELINE

  • SUTRO BIOPHARMA INC - INTENDS TO EXIT ITS INTERNAL GMP MANUFACTURING FACILITY BY YEAR-END

  • SUTRO BIOPHARMA INC - JANE CHUNG, PRESIDENT AND COO, TO SUCCEED BILL NEWELL AS CEO AND BOARD DIRECTOR

  • SUTRO BIOPHARMA INC - WILL REDUCE ITS ORGANIZATIONAL HEADCOUNT BY NEARLY 50 PERCENT

  • SUTRO BIOPHARMA INC - CASH PAYMENTS ASSOCIATED WITH RESTRUCTURING ARE ESTIMATED TO BE $40 TO $45 MILLION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI